COMMD7

Across TCGA pan-cancer cohorts, COMMD7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COMMD7 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher COMMD7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COMMD7 expression acts as an unfavorable survival marker.

LUSC, BLCA, and BRCA are the cancer types where COMMD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.086	0.664	<.001	26	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
BRCA	OS	Median	All	0.672	0.963	.026	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COMMD7–LUSC (OS)

Open the LUSC breakdown →